Contact us : info@bioworlde.com
Home > Product > Primary Antibodies
Smad3 (phospho-T179) polyclonal antibody AP0327
  • Western blot (WB) analysis of p-Smad3 (T179) polyclonal antibody at 1:500 dilution Lane1:HEK293T cell lysate treated with TNFa(20ng/ml,15mins) Lane2:Raw264.7 cell lysate treated with TNFa(20ng/ml,15mins) Lane3:PC12 cell lysate treated with TNFa(20ng/ml,15mins)
Product NameSmad3 (phospho-T179) polyclonal antibody
Catalog No.AP0327
Swiss-ProtP84022
Host Rabbit
ReactivityHuman,Mouse,Rat
ApplicationsWB
Application_allWB: 1:1000~1:2000
BiowMW~ 48, 55 kDa
Alternative NameMothers against decapentaplegic homolog 3; MAD homolog 3; Mad3; Mothers against DPP homolog 3; hMAD-3; JV15-2; SMAD family member 3; SMAD 3; Smad3; hSMAD3; SMAD3; MADH3
Purification&PurityThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
ConjugateUnconjugated
ModificationPhosphorylation
Browse similar products>>
Size Price
50ul $168
100ul $298
Add to cart My orders
Product Name :
Smad3 (phospho-T179) polyclonal antibody
Background :
Smad proteins, the mammalian homologs of the Drosophila mothers against decapentaplegic (Mad), have been implicated as downstream effectors of GFβ/BMP signaling. Smad1 (also designated Madr1 or JV4-1) and Smad5 are effectors of BMP-2 and BMP-4 function, while Smad2 (also designated Madr2 or JV18-1) and Smad3 are involved in TGFβ and activin-mediated growth modulation. Smad4 (also designated DPC4) has been shown to mediate all of the above activities through interaction with various Smad family members. Smad6 and Smad7 regulate the response to activin/TGFβ signaling by interfering with TGFβ-mediated phosphorylation of other Smad proteins.
Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :
p-Smad3 (T179) polyclonal antibody detects endogenous levels of Smad3 protein only when phosphorylated at Thr179.
Immunogen :
Synthetic phosphopeptide derived from human Smad3 around the phosphorylation site of Threonine 179.
Conjugate :
Unconjugated
Modification :
Phosphorylation
  • Western blot (WB) analysis of p-Smad3 (T179) polyclonal antibody at 1:500 dilution Lane1:HEK293T cell lysate treated with TNFa(20ng/ml,15mins) Lane2:Raw264.7 cell lysate treated with TNFa(20ng/ml,15mins) Lane3:PC12 cell lysate treated with TNFa(20ng/ml,15mins)
Anti‑fibrotic effects of Acremoniumterricola milleretal mycelium on immunological hepatic fibrosis in rats PMCID:    Pubmed No.:25270983 C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation PMCID:    Pubmed No.:25962701 CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation. PMCID:    Pubmed No.:26138247 Oroxylin A inhibits invasion and migration through suppressing ERK/GSK‐3β signaling in snail‐expressing non‐small‐cell lung cancer cells PMCID:    Pubmed No.:26741501 Novel hydrogen sulfide-releasing compound, S-propargyl-cysteine, prevents STZ-induced diabetic nephropathy PMCID:    Pubmed No.:27055593 Anti‑fibrotic effects of Acremoniumterricola milleretal mycelium on immunological hepatic fibrosis in rats PMCID:    Pubmed No.:25270983 Oroxylin A inhibits invasion and migration through suppressing ERK/GSK‐3β signaling in snail‐expressing non‐small‐cell lung cancer cells PMCID:    Pubmed No.:26741501 Novel hydrogen sulfide-releasing compound, S-propargyl-cysteine, prevents STZ-induced diabetic nephropathy PMCID:    Pubmed No.:27055593 CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation PMCID:    Pubmed No.:26138247 Novel hydrogen sulfide-releasing compound, S-propargyl-cysteine, prevents STZ-induced diabetic nephropathy PMCID:    Pubmed No.:27055593 Gambogic acid suppresses cancer invasion and migration by inhibiting TGFβ1-induced epithelial-to-mesenchymal transition PMCID:    Pubmed No.:28404892 The phosphorylation of the Smad2/3 linker region by nemo-like kinase regulates TGF-β signaling PMCID:    Pubmed No.:33676893 Epithelial and interstitial Notch1 activity contributes to the myofibroblastic phenotype and fibrosis PMCID:    Pubmed No.:31718671 CTRP15 derived from cardiac myocytes attenuates TGFβ1-induced fibrotic response in cardiac fibroblasts PMCID:    Pubmed No.:32424654 Fisetin Alleviates Atrial Inflammation, Remodeling, and Vulnerability to Atrial Fibrillation after Myocardial Infarction PMCID:    Pubmed No.:31666455
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.

Price/Size :

USD 368/1mg/vial



Tips: 

For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Describe :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.

Formula:

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.

Storage:

The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C. 


Note :

This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER